相关实验视频

Updated: Aug 8, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

纤维细胞生长因子受体基质2 (FRS2) 在一次性逆皮质脂肪瘤中的表达及其临床影响

W-D Chen¹, C-L Miao

¹Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, China. miaochengli7824@163.com.

European review for medical and pharmacological sciences

|July 17, 2023

概括

纤维细胞生长因子受体基质2 (FRS2) 在初级逆皮质脂肪瘤 (PRPLS) 组织中高度表达. 高FRS2表达与更差的预后有关,表明其作为PRPLS复发和生存的生物标志物的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
手术病理学手术病理学

背景情况:

主要逆皮质脂肪瘤 (PRPLS) 是一种罕见且具有攻击性的恶性瘤.
确定PRPLS可靠的预后标志物对于改善患者的治疗结果至关重要.

研究的目的:

研究PRPLS组织中纤维细胞生长因子受体基质2 (FRS2) 的表达水平.
为了确定FRS2表达与患者复发和存活率之间的相关性.

主要方法:

对87名接受了彻底手术的PRPLS患者进行了回顾性分析.
免疫组织化学染色以评估FRS2蛋白质表达.
多变量考克斯回归分析以确定独立的预后因素.

主要成果:

在62.07%的PRPLS病例中表达了FRS2蛋白.
阳性FRS2表达与较差的病理类型,国家癌症控制中心联合会 (FNCLCC) 等级,瘤数量,阳性边缘和复发/转移 (p<0.05) 显著相关.
阳性FRS2表达的患者的无进展生存期 (PFS) 和整体生存期 (OS) 显著缩短 (p<0.05).
FRS2表达是5年无病生存期 (DFS) 和OS (p<0.05) 的独立预测指标.

结论:

FRS2经常表达为PRPLS,并且与不良预后因素有显著的相关性.
FRS2有可能成为预测PRPLS患者复发和生存的有价值生物标志物.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...